InSightec Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tirat Carmel Israel (1999)

Organization Overview

First Clinical Trial
2020
NCT04417088
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

InSightec

Active Ingredients

Drugs in Phase 3 Trials (1)

pembrolizumab (keytruda) (2 trials)

Drugs in Phase 2 Trials (2)

carboplatin (paraplatin) (2 trials)

doxorubicin (Doxil) (2 trials)

Drugs in Phase 1 Trials (1)

aducanumab (Aduhelm) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 4